Christopher B Hurt1, Delesha M Carpenter2, Donna M Evon3, Caitlin M Hennessy4, Sarah K Rhea4, William A Zule4. 1. Institute for Global Health & Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Division of Gastroenterology & Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. RTI International, Research Triangle Park, North Carolina.
Abstract
PURPOSE: To characterize how health care providers in western North Carolina (NC) manage patients with substance use disorders and to inform strategies for preventing injection drug use (IDU)-associated outbreaks of bloodborne infectious diseases. METHODS: We collected data on practice characteristics, provider sociodemographics, and attitudes and beliefs about hepatitis C virus (HCV), human immunodeficiency virus (HIV), opioid use, and IDU via online survey. Providers in 8 counties of western NC were invited to participate by email. Results were analyzed using descriptive and bivariate statistics. FINDINGS: Of 84 respondents participating between 30 July and 3 December 2018, 81% were practicing clinicians and 46% served a county identified as being vulnerable to IDU-associated outbreaks of HCV or HIV. A substantial proportion was unsure about injecting behaviors among patients. Scores reflected comfort working with opioid users, though this varied by medical specialty. One-quarter of respondents "never" discussed harm reduction or HCV treatment with patients known to inject drugs; 22% "never" discussed HIV screening with injectors; and 1 in 3 referred at-risk patients out for HCV or HIV testing rather than ordering a test themselves. Scores indicated low levels of stigma toward persons living with HCV or HIV. Respondents identified HIV treatment, HCV treatment, and liver disease management as training needs. CONCLUSIONS: Our findings provide insights to inform health infrastructure improvement, with the goal of preventing HCV or HIV outbreaks in southern Appalachia. Rural health care workers are willing to receive additional training if it can improve care for patients affected by substance use disorders.
PURPOSE: To characterize how health care providers in western North Carolina (NC) manage patients with substance use disorders and to inform strategies for preventing injection drug use (IDU)-associated outbreaks of bloodborne infectious diseases. METHODS: We collected data on practice characteristics, provider sociodemographics, and attitudes and beliefs about hepatitis C virus (HCV), human immunodeficiency virus (HIV), opioid use, and IDU via online survey. Providers in 8 counties of western NC were invited to participate by email. Results were analyzed using descriptive and bivariate statistics. FINDINGS: Of 84 respondents participating between 30 July and 3 December 2018, 81% were practicing clinicians and 46% served a county identified as being vulnerable to IDU-associated outbreaks of HCV or HIV. A substantial proportion was unsure about injecting behaviors among patients. Scores reflected comfort working with opioid users, though this varied by medical specialty. One-quarter of respondents "never" discussed harm reduction or HCV treatment with patients known to inject drugs; 22% "never" discussed HIV screening with injectors; and 1 in 3 referred at-risk patients out for HCV or HIV testing rather than ordering a test themselves. Scores indicated low levels of stigma toward persons living with HCV or HIV. Respondents identified HIV treatment, HCV treatment, and liver disease management as training needs. CONCLUSIONS: Our findings provide insights to inform health infrastructure improvement, with the goal of preventing HCV or HIV outbreaks in southern Appalachia. Rural health care workers are willing to receive additional training if it can improve care for patients affected by substance use disorders.
Authors: Kristi L Stringer; Bulent Turan; Lisa McCormick; Modupeoluwa Durojaiye; Laura Nyblade; Mirjam-Colette Kempf; Bronwen Lichtenstein; Janet M Turan Journal: AIDS Behav Date: 2016-01
Authors: Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller Journal: Curr HIV/AIDS Rep Date: 2018-06 Impact factor: 5.071
Authors: Shauna Onofrey; Jasneet Aneja; Gillian A Haney; Ellen H Nagami; Alfred DeMaria; Georg M Lauer; Kelsey Hills-Evans; Kerri Barton; Stephanie Kulaga; Melinda J Bowen; Noelle Cocoros; Barbara H McGovern; Daniel R Church; Arthur Y Kim Journal: Ann Intern Med Date: 2015-08-18 Impact factor: 25.391
Authors: Cyprian Wejnert; Kristen L Hess; H Irene Hall; Michelle Van Handel; Demorah Hayes; Paul Fulton; Qian An; Linda J Koenig; Joseph Prejean; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2016-12-02 Impact factor: 17.586
Authors: Michelle M Van Handel; Charles E Rose; Elaine J Hallisey; Jessica L Kolling; Jon E Zibbell; Brian Lewis; Michele K Bohm; Christopher M Jones; Barry E Flanagan; Azfar-E-Alam Siddiqi; Kashif Iqbal; Andrew L Dent; Jonathan H Mermin; Eugene McCray; John W Ward; John T Brooks Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Philip J Peters; Pamela Pontones; Karen W Hoover; Monita R Patel; Romeo R Galang; Jessica Shields; Sara J Blosser; Michael W Spiller; Brittany Combs; William M Switzer; Caitlin Conrad; Jessica Gentry; Yury Khudyakov; Dorothy Waterhouse; S Michele Owen; Erika Chapman; Jeremy C Roseberry; Veronica McCants; Paul J Weidle; Dita Broz; Taraz Samandari; Jonathan Mermin; Jennifer Walthall; John T Brooks; Joan M Duwve Journal: N Engl J Med Date: 2016-07-21 Impact factor: 91.245
Authors: Jon E Zibbell; Rachel Hart-Malloy; John Barry; Lillian Fan; Colleen Flanigan Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308